Please assess the completion status of the following clinical trial:

Trial Title: Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Indolent lymphoma including Grades 1-3a follicular, small lymphocytic, lymphoplasmacytic, and marginal zone lymphoma; Stages III-IV, or bulky disease, Stage II. Tumor verified CD20+ and CT imaging done at screening verifying disease~* Indolent B-cell NHL that remains stable or unresponsive during or within 6 months of treatment with rituximab or a rituximab-containing regimen~* Indolent lymphoma including grades 1-3a follicular, small lymphocytic, lymphoplasmacytic, and marginal zone lymphoma; stages III-IV, or bulky disease stage II (i.e. as any single mass \> 5 cm in any direction)~* ECOG Performance Status of 0, 1, or 2~* Life expectancy of at least 6 months~* 18 years or older~* Signed, written informed consent~Exclusion Criteria:~* Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to aggressive lymphoma~* Previous allogeneic stem cell transplant~* Previous autologous stem cell transplant, fludarabine therapy, or radioimmunotherapy in the past 12 months~* Previous external beam radiation therapy to the pelvis. Previous external beam radiation therapy for bony disease to the cranium, mediastinum, and axilla, or to two or to more than 3 vertebral bodies~* High dose steroids greater to or equal to 60 mg prednisone/day (or equivalent) within 3 months of randomization. No more than 10 mg prednisone (or equivalent) daily at the time of randomization~* Prior bendamustine treatment within 1 year of randomization not resulting in a CR or PR for at least 6 months~* Treatment with anti-CD20 monoclonal antibody within 3 months of randomization~* Known CNS involvement of indolent lymphoma~* Other past or current malignancy. Subjects free of malignancy for at least 5 years or have history of definitively treated non-melanoma skin cancer, or successfully treated in situ carcinoma, are eligible~* Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment~* Clinically significant cardiac disease~* History of significant cerebrovascular disease or event with significant symptoms~* Positive serology for Hepatitis B~* Current active liver or biliary disease (except Gibber's syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease)~* Known HIV positive~* Abnormal/inadequate blood values, liver and kidney function~* Current participation in other clinical study~* Inability to comply with the protocol activities~* Lactating or pregnant women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ofatumumab and Bendamustine (Arm A) (Type: EXPERIMENTAL): Up to 8 cycles of bendamustine (90 mg/m2) on Days 1,2 every 21 days with12 doses of ofatumumab (1000 mg, Day 1 q21 days when with bendamustine and q28 days when given as monotherapy)
- Bendamustine (Arm B) (Type: ACTIVE_COMPARATOR): Up to 8 cycles of bendamustine (120 mg/m2) on Days 1,2 every 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy